Search Results

You are looking at 81 - 90 of 2,659 items for :

  • Refine by Access: Content accessible to Me x
Clear All
Full access

Prognosis of Incidental Brain Metastases in Patients With Advanced Renal Cell Carcinoma

Ritesh R. Kotecha, Ronan Flippot, Taylor Nortman, Annalisa Guida, Sujata Patil, Bernard Escudier, Robert J. Motzer, Laurence Albiges, and Martin H. Voss

in mRCC and characterize outcomes in this specific patient population. Patients and Methods After obtaining Institutional Review Board approval at Gustave Roussy and Memorial Sloan Kettering Cancer Center, a retrospective multicenter chart

Full access

CRE24-046: Social Determinants of Health in Real-World Evidence Studies of Early-Stage Cancer Care: A Systematic Literature Review

Thomas Wilson, Andrew Osterland, Sarah Markt, Arthur Sillah, Junqing Liu, Esther Renee Smith-Howell, Gregory Patton, and Kashif Firozvi

SDOH, this study identified data sources, definitions, and measures of SDOH used in observational studies of early-stage cancer. Methods: We conducted a systematic literature review of observational studies focused on the impact of SDOH on early

Full access

CLO24-092: Neoadjuvant Tyrosine Kinase Inhibitors (TKIs) Efficacy in EGFR Positive Stage III Non–Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis

John Kelvin Lalusis and John Lois Padayao

of overall response rate, disease free and overall survival. This systematic review and meta-analysis assessed the efficacy of neoadjuvant TKI compared to standard chemotherapy regimen in terms of objective response rate (ORR). Methods: A systematic

Full access

HSR22-149: Adverse Events Among Cancer Patients Treated With a Combination of Nivolumab and Ipilimumab as Compared to Nivolumab Monotherapy: A Systematic Review and Meta-Analysis

Shweta Kamat, Jay Patel, Britny Brown, and Ami Vyas

Objectives : Combination immune checkpoint inhibitors (ICIs) have demonstrated long-term clinical benefit but are associated with serious treatment-related adverse events (TRAEs). We performed a systematic review and meta-analysis to examine the

Full access

QIM23-131: A Retrospective Review of Myelodysplastic Syndrome Management (MDS) at Watson Clinic LLP: From Diagnosis to Primary Course of Treatment

Shane Burke, Galina Vugman, Noreen McGowan, and Michelle Sharrett

peripheral blood and bone marrow evaluation to measure extent of disease and risk of progression. Methods: A retrospective review of 69 patients diagnosed with MDS between Jan 1, 2015–Dec 31, 2019 at a community based cancer center was performed to

Full access

HSR21-067: What Patient-Reported Outcomes Are Being Used in Non-small Cell Lung Cancer? A Targeted Literature Review of Randomized Clinical Trials and Regulatory Labeling

Kajal Patel, Soham Shukla, Jennifer Hanlon, Kelly Bell, Laurie Eliason, and Cosmina Hogea

ePROVIDE, an online resource of clinical outcomes assessment, for inclusion of PRO claims in FDA or EMA drug labeling, and clinicaltrials.gov for PRO inclusion as an endpoint in NSCLC randomized clinical trials. Prescribing information was reviewed from

Full access

CLO24-059: The Impact of Proton Pump Inhibitors on Palbociclib in Advanced Breast Cancer Patients: A Systematic Review and Meta-Analysis

Yu-Cheng Chang, Junmin Song, Kuan-Yu Chi, Pei-Chin Chen, Aarushi Sudan, Chin-Hsuan Huang, and Yu Chang

patients. We conducted a systematic review and meta-analysis to investigate the impact of PPIs on Palbociclib in HR+, HER2- metastatic breast cancer patients. Method: Electronic databases of PubMed, Embase, and Cochrane Library were searched from

Full access

CLO22-045: Gastrointestinal Safety Profile of Sonic Hedgehog Inhibitors in Basal Cell Carcinoma (BCC): A Systematic Review and Meta-analysis

Muhammad Zain Farooq, Mishal Shan Siddiqui, Syed Ali Farhan, Mahima Khatri, Syed Hamza Bin Waqar, Saad Khalid, and Ankit Mangla

reporting adverse events (AE) were excluded. All AEs were reported for phase II trials, while toxicities occurring up to the maximally tolerated dose (MTD) were noted for patients in phase I dose-escalation trials. Results were pooled via Review Manager v5

Full access

HSR23-110: Immune Checkpoint Inhibitor (ICI) Treatment After Progression on Anti–PD-1 Therapy in Advanced Melanoma: A Systematic Review of the Literature

Daniel Olson, Brian Gastman, Alicia Rowell, Madan Jagasia, Parameswaran Hari, Wen Shi, Kendall Stevinson, and Katy K. Tsai

inconsistent reporting of response criteria and methods for mPFS and mOS. Conclusion: ICI retreatment is used in clinical practice; however, our systematic literature review found no randomized trials supporting the use of ICI after anti–PD-1. Limited

Full access

EPR21-037: Prevalence of Low HER2 Expression Among HER2 Negative Metastatic Breast Cancer Patients in U.S: Multi-Site, Retrospective Chart Review Study

Sandhya Mehta, Winghan Kwong, Angelica Falkenstein, Melissa Pavilack, and Jonathan Kish

Provider Extended Network (OPEN) who had treated ≥1 BC patient in the past 12 months (n=504) were invited to participate in a retrospective chart review study. Participating physicians submitted data for up to 5 HER2-ve mBC patients who had received any